Bristol-Myers Squibb's share price has been going through the roof due to the company's emergence as a leader in the field of immuno-oncology. This big pharma's high-flying days might be numbered, however. Here's why.
Bristol-Myers Squibb's hepatitis C sales topped AbbVie's in the first quarter. Is this trend set to continue?
Bristol-Myers posts a much stronger first quarter than expected. Here's what investors need to know.
Bristol-Myers Squibb is pinning its future on a new class of drugs that could be game-changers in the fight against cancer. The Street, though, may be wildly overestimating their commercial potential. Here's why.
Despite the threat of patent losses, our analysts believe these Big Pharma stocks would be smart investments over the next 20 years.
Shares of uniQure burst higher today. Here's why.
These three healthcare stocks could offer the best blend of sales and dividend growth in the sector.
Three contributors weigh in.
Bristol-Myers Squibb is pursuing FDA approval that would allow its daclatasvir to be used alongside Sovaldi in genotype 3 patients.
Pfizer and Bristol-Myers Squibb are two top dividend stocks. Which one offers the better investing opportunity going forward?